文献速递血栓与止血

免疫性血小板减少症的早期免疫调节——2022年瑞士伦策海德ICIS会议报告

Early immunomodulation in immune thrombocytopenia-A report of the ICIS meeting in Lenzerheide, Switzerland 2022.
PubMed 文献 · Br J Haematol · 2023-01-01

该文为2022年瑞士伦策海德ICIS会议报告,讨论通过早期恢复对血小板的免疫耐受来防止免疫性血小板减少症(ITP)进展为难治性。文章提出持续无治疗缓解(SROT)的临床定义,并指出血小板生成素受体激动剂(TPO-RAs)作为一线治疗显示出免疫调节和免疫耐受特性,但需更多免疫学研究明确可被治疗逆转的分子改变。

要点

  • 防止ITP进展为难治性的唯一途径可能是在疾病早期恢复对血小板的免疫耐受。
  • 持续无治疗缓解(SROT)描述可安全停用ITP治疗并维持缓解状态的患者。
  • TPO-RAs作为一线治疗显示出免疫调节和免疫耐受特性,但需更多免疫学研究。

核心结论

  • 防止ITP成为难治性的唯一方法可能是在疾病早期恢复对血小板的耐受。
  • 多种免疫异常可能在慢性ITP中累积,治愈机会随时间显著下降。
  • TPO-RAs作为一线治疗显示出有希望的结果,但需更多免疫学研究确定ITP中可被治疗逆转的准确分子改变。

研究设计与样本

  • 该文为2022年在瑞士伦策海德举行的ICIS会议报告。

主要发现

  • 持续无治疗缓解(SROT)是描述可安全停用ITP治疗并维持缓解状态患者的临床定义。
  • 目前正在评估不同治疗策略以达到SROT,多联合靶向先天性和/或适应性免疫系统、炎症状态及增加血小板负荷的药物。
  • TPO-RAs似乎具有免疫调节和免疫耐受特性,不仅增加血小板抗原质量,还增加转化生长因子-β浓度,并刺激调节性T和B淋巴细胞。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更多免疫学研究来确定ITP中可能通过治疗逆转的准确分子改变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The only way to prevent immune thrombocytopenia (ITP) from becoming refractory would be to restore tolerance to platelets at an early phase of the disease. Numerous immune alterations probably accumulate in chronic ITP; thus, the chances of cure decrease significantly with time. Currently, sustained remission off treatment (SROT) is a clinical definition describing patients who can discontinue their ITP treatment without risk and maintain a state of remission. Different treatment strategies are presently being evaluated with the goal of attaining SROT, mostly combining drugs targeting the innate and/or the adaptive immune system, the inflammation state, so as increasing the platelet load. In this sense, thrombopoietin receptor agonists (TPO-RAs) have shown promising results if used as upfront treatment. TPO-RAs seem to exhibit immunomodulation and immune tolerance properties, increasing not only the platelet antigen mass but also increasing the transforming growth factor-β concentration, and stimulating regulatory T and B lymphocytes. However, more immunological studies are needed to establish accurate molecular alterations in ITP that are potentially reversed with treatments.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. González-López TJ, Schifferli A. Early immunomodulation in immune thrombocytopenia-A report of the ICIS meeting in Lenzerheide, Switzerland 2022. Br J Haematol. 2023. PMID: 37735547. doi:10.1111/bjh.19082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。